The following is the agenda for this morning's Testing call.  I have also
attached the email John had previously sent from Steve Lazarus.  I believe
we had all pretty much agreed that Steve's comments should be forwarded to
the Transactions SWG, but we want to get your agreement on that this
morning.

The number again is 703/736-7290, pin 1315339#.  The time of the call is
11:00 AM EST.

Agenda
- Housekeeping Reminders (5 minutes)
- Phoenix Panel Discussion (5 minutes)
- Agree on Transactions Receiving S. Lazarus Comments (5 minutes)
- B2B WP Suggested Revisions (25 minutes)
- Test Data Technical Scenarios Status (10 minutes)
- Test Data "Repository" (if time permits) (10 minutes)

----- Original Message -----
From: <[EMAIL PROTECTED]>
To: <[EMAIL PROTECTED]>
Sent: Friday, September 06, 2002 11:27 AM
Subject: Comments on White Paper


> Hello all,
>
> Per our call yesterday, below are the comments we need to consider from
> Steve Lazarus.  Give them some thought and we will discuss further on the
> 19th.
>
> Page 4, near the top.  I think that there are at least three major
problems
> that need to be outline here to illustrate a point which is discussed, but
> not emphasized.  It is one that is easily overlooked until one actually
> gets into the testing process.  The three problems are:
>
>       a. Translators do not support all of the data elements because some
>          do not have one to one translations.
>       b. Print files for UB92 and HCFA1500 do not contain all of the data
>          elements required for the 837, nor do all the data elements have
>          the same definitions as for the 837.  This is a huge issue which
>          can not be addressed by sending the print file to the
>          clearinghouse.
>       c. Source systems, as well as billing applications, must be upgraded
>          to provide for total data capture and the new definitions of the
>          data elements.
>
>          _______________________________________________
>
>          John Lilleston
>          Technical Supervisor
>          Verizon Information Technologies, Inc.
>          Healthcare Solutions
>          813-979-3225
>          [EMAIL PROTECTED]
>          http://www.VerizonIT.com/
>          _______________________________________________
>
>
> To be removed from this listserv, please email [EMAIL PROTECTED]
> <P>The WEDI SNIP listserv to which you are subscribed is not moderated.
The
> discussions on this listserv therefore represent the views of the
individual
> participants, and do not necessarily represent the views of the WEDI Board
of
> Directors nor WEDI SNIP.  If you wish to receive an official opinion, post
> your question to the WEDI SNIP Issues Database at
> http://snip.wedi.org/tracking/.
> Posting of advertisements or other commercial use of this listserv is
> specifically prohibited.
>
>
>
>


"Empire Health Choice Inc." made the following
 annotations on 09/19/02 09:47:17
------------------------------------------------------------------------------

[INFO] -- Access Manager:
Attention!  This electronic message contains information that may be legally 
confidential and/or privileged.  The information is intended solely for the individual 
or entity named above and access by anyone else is unauthorized.  If you are not the 
intended recipient, any disclosure, copying, distribution, or use of the contents of 
this information is prohibited and may be unlawful.  If you have received this 
electronic transmission in error, please reply immediately to the sender that you have 
received the message in error, and delete it.




To be removed from this listserv, please email [EMAIL PROTECTED]
<P>The WEDI SNIP listserv to which you are subscribed is not moderated.  The
discussions on this listserv therefore represent the views of the individual
participants, and do not necessarily represent the views of the WEDI Board of
Directors nor WEDI SNIP.  If you wish to receive an official opinion, post
your question to the WEDI SNIP Issues Database at
http://snip.wedi.org/tracking/.
Posting of advertisements or other commercial use of this listserv is
specifically prohibited.

Reply via email to